Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Russell D. Cohen

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Gastroenterology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162. PMID: 30809655.
      View in: PubMed
    2. Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110. PMID: 30726894.
      View in: PubMed
    3. Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024. PMID: 30726887.
      View in: PubMed
    4. Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-Marketing Data. J Crohns Colitis. 2019 Aug 13. PMID: 31504340.
      View in: PubMed
    5. Israel A, Christensen B, El Jurdi K, Rai V, Ollech J, Cohen RD, Sakuraba A, Dalal S, Rubin DT. Follow-Up of Ulcerative Colitis Patients Who Have Achieved Histological Normalization. Clin Gastroenterol Hepatol. 2019 Jun 20. PMID: 31228567.
      View in: PubMed
    6. Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 Jun 11. PMID: 31187322.
      View in: PubMed
    7. Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Jun 06. PMID: 31169926.
      View in: PubMed
    8. Alpert L, Yassan L, Poon R, Kadri S, Niu N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, Zhen CJ, Cohen RD, Rubin DT, Pekow JR, Weber CR, Xiao SY, Hart J, Segal J, Setia N. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 Jul; 89:44-50. PMID: 31054900.
      View in: PubMed
    9. Lu TX, Cohen RD. Maneuvering Clinical Pathways for Crohn's Disease. Curr Gastroenterol Rep. 2019 Apr 23; 21(5):20. PMID: 31016466.
      View in: PubMed
    10. Sossenheimer PH, Glick LR, Dachman AH, Skowron KB, Rubin MA, Umanskiy K, Smith R, Cannon LM, Hurst RD, Cohen RD, Hyman NH, Rubin DT. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469. PMID: 30540661.
      View in: PubMed
    11. Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 Jul; 64(7):1945-1951. PMID: 30734234.
      View in: PubMed
    12. Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275. PMID: 30738034.
      View in: PubMed
    13. Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JJ. Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-a4ß7 and anti-PD1 antibodies. J Immunother Cancer. 2019 01 06; 7(1):1. PMID: 30612589.
      View in: PubMed
    14. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 10; 63(10):2815. PMID: 30136047.
      View in: PubMed
    15. Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940. PMID: 30126019.
      View in: PubMed
    16. Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688. PMID: 30022113.
      View in: PubMed
    17. Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544. PMID: 28723860.
      View in: PubMed
    18. Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297. PMID: 29506124.
      View in: PubMed
    19. Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206. PMID: 29751167.
      View in: PubMed
    20. Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 Feb; 17(3):486-493. PMID: 29751166.
      View in: PubMed
    21. Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860. PMID: 29562271.
      View in: PubMed
    22. Mak WY, Buisson A, Andersen MJ, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301. PMID: 29468374.
      View in: PubMed
    23. Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509. PMID: 29462385.
      View in: PubMed
    24. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501. PMID: 29462395.
      View in: PubMed
    25. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024. PMID: 29417331.
      View in: PubMed
    26. Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309. PMID: 29307473.
      View in: PubMed
    27. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 12 04; 11(12):1510. PMID: 28453665.
      View in: PubMed
    28. Cohen RD. Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 Nov; 13(11):697-699. PMID: 29230150.
      View in: PubMed
    29. Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):99-105. PMID: 28870657.
      View in: PubMed
    30. Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900. PMID: 28837634.
      View in: PubMed
    31. Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429. PMID: 28719595.
      View in: PubMed
    32. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791. PMID: 28333362.
      View in: PubMed
    33. Meckel K, Li YC, Lim J, Kocherginsky M, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20. PMID: 27281309.
      View in: PubMed
    34. Saad AM, Czul F, Sakuraba A, Rubin DT, Cohen RD. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31. PMID: 26919459.
      View in: PubMed
    35. Krugliak Cleveland N, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Rubin DT. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7. PMID: 26658214.
      View in: PubMed
    36. Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize Anti-TNF-a Therapy in Patients With IBD. Curr Treat Options Gastroenterol. 2016 Mar; 14(1):83-90. PMID: 26872815.
      View in: PubMed
    37. Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7. PMID: 26725061.
      View in: PubMed
    38. Dalal SR, Cohen RD. What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. Gastroenterol Hepatol (N Y). 2015 Oct; 11(10):657-65. PMID: 27330493.
      View in: PubMed
    39. Cohen RD, Dalal SR. Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. Inflamm Bowel Dis. 2015 Jul; 21(7):1719-36. PMID: 26020604.
      View in: PubMed
    40. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative Colitis Care Pathway. Gastroenterology. 2015 Jul; 149(1):238-45. PMID: 26025078.
      View in: PubMed
    41. Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25. PMID: 26001336.
      View in: PubMed
    42. Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015 Jun; 18(6):447-56. PMID: 25728698.
      View in: PubMed
    43. Stein AC, Rubin DT, Hanauer SB, Cohen RD. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8. PMID: 25171509.
      View in: PubMed
    44. Stein AC, Cohen RD. Dietary fiber intake and Crohn's disease. Gastroenterology. 2014 Apr; 146(4):1133. PMID: 24576734.
      View in: PubMed
    45. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23. PMID: 24394749.
      View in: PubMed
    46. Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013 Dec; 19(13):2778-86. PMID: 24185311.
      View in: PubMed
    47. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83. PMID: 24132161.
      View in: PubMed
    48. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4. PMID: 23872237.
      View in: PubMed
    49. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6. PMID: 23429449.
      View in: PubMed
    50. Yen L, Wu J, Hodgkins PL, Cohen RD, Nichol MB. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012 Nov-Dec; 18(9):701-12. PMID: 23206213.
      View in: PubMed
    51. Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012 Sep 24; 12:132. PMID: 23006789.
      View in: PubMed
    52. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22. PMID: 22890223.
      View in: PubMed
    53. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32. PMID: 22311366.
      View in: PubMed
    54. Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6. PMID: 21456032.
      View in: PubMed
    55. Oliveira L, Cohen RD. Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. Drug Des Devel Ther. 2011 Feb 27; 5:111-6. PMID: 21448448.
      View in: PubMed
    56. Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):103-9. PMID: 20134492.
      View in: PubMed
    57. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010 Apr; 31(7):693-707. PMID: 20064142.
      View in: PubMed
    58. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. PMID: 19408340.
      View in: PubMed
    59. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009 Aug; 43(7):613-6. PMID: 19142167.
      View in: PubMed
    60. Cohen RD. How should we treat severe acute steroid-refractory ulcerative colitis? Inflamm Bowel Dis. 2009 Jan; 15(1):150-1. PMID: 18844216.
      View in: PubMed
    61. Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis. 2008 Dec; 14(12):1707-14. PMID: 18618630.
      View in: PubMed
    62. Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008 Dec; 10(6):585-90. PMID: 19006615.
      View in: PubMed
    63. Cohen RD. What is the optimal maintenance treatment for ulcerative colitis? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S236-7. PMID: 18816679.
      View in: PubMed
    64. Cohen R, Robinson D, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008 Jun; 14(6):738-43. PMID: 18300281.
      View in: PubMed
    65. Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007 Nov; 62(11):1013-4. PMID: 17965080.
      View in: PubMed
    66. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007 Nov 01; 26(9):1179-86. PMID: 17944732.
      View in: PubMed
    67. Kedia P, Cohen RD. Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Ther Clin Risk Manag. 2007 Oct; 3(5):919-27. PMID: 18473016.
      View in: PubMed
    68. Thomas T, Cohen RD. Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007 Oct; 1(1):101-12. PMID: 19072439.
      View in: PubMed
    69. Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007 Jun; 10(3):185-94. PMID: 17547857.
      View in: PubMed
    70. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004. PMID: 17451704.
      View in: PubMed
    71. Cohen RD, Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):867-82. PMID: 17129818.
      View in: PubMed
    72. Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006 Oct; 12(10):972-8. PMID: 17012968.
      View in: PubMed
    73. Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006 Oct; 12(10):979-94. PMID: 17012969.
      View in: PubMed
    74. Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol. 2006 Sep; 40(8):669-77. PMID: 16940876.
      View in: PubMed
    75. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Aug 01; 24(3):465-74. PMID: 16886912.
      View in: PubMed
    76. Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex. 2006 Jul-Sep; 71(3):351-401. PMID: 17140062.
      View in: PubMed
    77. Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr Treat Options Gastroenterol. 2006 Jun; 9(3):234-45. PMID: 16901387.
      View in: PubMed
    78. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30. PMID: 16678077.
      View in: PubMed
    79. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. PMID: 16606351.
      View in: PubMed
    80. Robinson D, Hackett M, Wong J, Kimball AB, Cohen R, Bala M. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006 May; 22(5):989-1000. PMID: 16709321.
      View in: PubMed
    81. Cohen RD. MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006 May; 130(6):1923-4. PMID: 16697759.
      View in: PubMed
    82. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):940-87. PMID: 16530532.
      View in: PubMed
    83. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):935-9. PMID: 16530531.
      View in: PubMed
    84. Cohen RD. Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results? Gastroenterology. 2006 Feb; 130(2):607-8; discussion 608. PMID: 16472614.
      View in: PubMed
    85. Keswani RN, Cohen RD. Postoperative management of ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005 Dec; 7(6):492-9. PMID: 16313880.
      View in: PubMed
    86. Cohen RD. Worms, germs and IBD: is it your mother's fault? Gastroenterology. 2005 Sep; 129(3):1127-8; discussion 1128-9. PMID: 16143151.
      View in: PubMed
    87. Cohen RD. Mycobacterium in Crohn's: something to ruminate about? Gastroenterology. 2005 Jun; 128(7):2167-8. PMID: 15940650.
      View in: PubMed
    88. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8. PMID: 15771759.
      View in: PubMed
    89. Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005 Jan 06; 57(2):281-302. PMID: 15555743.
      View in: PubMed
    90. Cohen RD. Treating ulcerative colitis without medications--"look mom, no drugs!". Gastroenterology. 2005 Jan; 128(1):235-6. PMID: 15633142.
      View in: PubMed
    91. Ross AS, Cohen RD. Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep. 2004 Dec; 6(6):488-95. PMID: 15527679.
      View in: PubMed
    92. Cohen RD. Sperm, sex, and 6-MP: the perception on conception. Gastroenterology. 2004 Oct; 127(4):1263-4. PMID: 15481005.
      View in: PubMed
    93. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. PMID: 15447761.
      View in: PubMed
    94. Cohen RD. Mesalamine in IBD: multiple hats? Gastroenterology. 2004 Sep; 127(3):1001-2; discussion 1002. PMID: 15362058.
      View in: PubMed
    95. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9. PMID: 15362027.
      View in: PubMed
    96. Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004 Jun; 33(2):235-50, viii. PMID: 15177536.
      View in: PubMed
    97. Wang HL, Shah AG, Yerian LM, Cohen RD, Hart J. Collagenous gastritis: an unusual association with profound weight loss. Arch Pathol Lab Med. 2004 Feb; 128(2):229-32. PMID: 14736276.
      View in: PubMed
    98. Cohen RD. IBD researchers reach for the "tabloid". Gastroenterology. 2004 Feb; 126(2):611-2. PMID: 14762801.
      View in: PubMed
    99. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004; 64(16):1767-77. PMID: 15301561.
      View in: PubMed
    100. Cohen RD. Infliximab at 5 years--tweaking the recipe for success? Gastroenterology. 2003 Dec; 125(6):1902-3. PMID: 14724849.
      View in: PubMed
    101. Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology. 2003 Sep; 125(3):982-4. PMID: 12949746.
      View in: PubMed
    102. Cohen RD. Infliximab in ulcerative colitis: is there a placebo (effect) in the house? Gastroenterology. 2003 Jun; 124(7):1990-1; discussion 1991. PMID: 12806639.
      View in: PubMed
    103. Cohen RD. IBD: the drugs work...but do the patients? Am J Gastroenterol. 2003 Apr; 98(4):722-3. PMID: 12738447.
      View in: PubMed
    104. Cohen RD. The mesalamine wars heat up-enter balsalazide. Gastroenterology. 2003 Feb; 124(2):574-5. PMID: 12557164.
      View in: PubMed
    105. Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2002 Dec; 4(6):497-505. PMID: 12441040.
      View in: PubMed
    106. Cohen RD. Methotrexate in IBD--move over 6-MP? Not so fast... Gastroenterology. 2002 Nov; 123(5):1737-9. PMID: 12404250.
      View in: PubMed
    107. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002 Sep; 16(9):1603-9. PMID: 12197839.
      View in: PubMed
    108. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002 Aug; 35(2):151-6. PMID: 12172361.
      View in: PubMed
    109. Lee SD, Cohen RD. Endoscopy of the small bowel in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002 Jul; 12(3):485-93. PMID: 12486940.
      View in: PubMed
    110. Cohen RD. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology. 2002 Jun; 122(7):2082-4; discussion 2084. PMID: 12078667.
      View in: PubMed
    111. Levitsky J, Harrison JR, Cohen RD. Crohn's disease and Takayasu's arteritis. J Clin Gastroenterol. 2002 Apr; 34(4):454-6. PMID: 11907362.
      View in: PubMed
    112. Cohen RD. Cost utility of initial medical management for Crohn's disease perianal fistula. Gastroenterology. 2002 Apr; 122(4):1187-8; author reply 1188-90. PMID: 11910380.
      View in: PubMed
    113. Lee SD, Cohen RD. Endoscopy in inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):119-32. PMID: 12122727.
      View in: PubMed
    114. Cohen RD. Infliximab as first-line therapy for severe Crohn's disease? Inflamm Bowel Dis. 2002 Jan; 8(1):58-9; discussion 63-5. PMID: 11837940.
      View in: PubMed
    115. Baron BW, Jeon HR, Glunz C, Peterson A, Cohen R, Hanauer S, Rubin D, Hart J, Baron JM. First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6. PMID: 12494414.
      View in: PubMed
    116. Chung PY, Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2001 Dec; 3(6):464-70. PMID: 11696283.
      View in: PubMed
    117. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33. PMID: 11693328.
      View in: PubMed
    118. Cohen RD. Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology. 2001 May; 120(6):1541-3. PMID: 11313325.
      View in: PubMed
    119. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22. PMID: 11380038.
      View in: PubMed
    120. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44. PMID: 11136276.
      View in: PubMed
    121. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77. PMID: 11151879.
      View in: PubMed
    122. Cohen RD. The cost of Crohn's disease: drugs or surgery? BioDrugs. 2000 Nov; 14(5):331-44. PMID: 18034577.
      View in: PubMed
    123. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76. PMID: 10811338.
      View in: PubMed
    124. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000 Feb; 95(2):524-30. PMID: 10685762.
      View in: PubMed
    125. Hurst RD, Cohen RD. The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. Semin Gastrointest Dis. 2000 Jan; 11(1):10-7. PMID: 10706225.
      View in: PubMed
    126. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7. PMID: 10579967.
      View in: PubMed
    127. Melander A, Olsson J, Lindberg G, Salzman A, Howard T, Stang P, Lydick E, Emslie-Smith A, Boyle DI, Evans JM, Macdonald TM, Bain J, Sullivan F. 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999. Diabetologia. 1999 Aug; 42(Suppl 1):A1-A330. PMID: 27770183.
      View in: PubMed
    128. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92. PMID: 10364029.
      View in: PubMed
    129. Cohen RD. Validation of health-related quality of life instruments. Hepatology. 1999 Jun; 29(6 Suppl):7S-8S. PMID: 10386075.
      View in: PubMed
    130. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 Feb; 5(1):1-10. PMID: 10028443.
      View in: PubMed
    131. Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28. PMID: 9829451.
      View in: PubMed
    132. Wallhagen MI, Strawbridge WJ, Cohen RD, Kaplan GA. An increasing prevalence of hearing impairment and associated risk factors over three decades of the Alameda County Study. Am J Public Health. 1997 Mar; 87(3):440-2. PMID: 9096550.
      View in: PubMed
    133. Cohen RD, Hanauer SB. Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology. 1996 May; 110(5):1658-62. PMID: 8613079.
      View in: PubMed
    134. Cohen RD, Hanauer SB. Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol. 1995 Dec; 90(12):2090-2. PMID: 8540493.
      View in: PubMed
    135. Wallhagen MI, Strawbridge WJ, Kaplan GA, Cohen RD. Impact of internal health locus of control on health outcomes for older men and women: a longitudinal perspective. Gerontologist. 1994 Jun; 34(3):299-306. PMID: 8076870.
      View in: PubMed
    136. Heimann TM, Cohen RD, Szporn A, Gil J. Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum. 1991 Jun; 34(6):449-54. PMID: 2036923.
      View in: PubMed
    137. Wingard DL, Cohn BA, Kaplan GA, Cirillo PM, Cohen RD. Sex differentials in morbidity and mortality risks examined by age and cause in the same cohort. Am J Epidemiol. 1989 Sep; 130(3):601-10. PMID: 2764004.
      View in: PubMed
    138. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc. 1980 Mar; 55(3):146-55. PMID: 6101626.
      View in: PubMed
    Cohen's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _